Postmarketing Phase IV Tumor necrosis factor (TNF) inhibitor therapies (anti-TNFs) are used routinely as first-line biotherapy for the treatment of rheumatoid arthritis (RA) and spondyloarthritis (SpA: psoriatic arthritis [PsA] and ankylosing spondylitis [AS]) in patients who have failed traditional non-biologic disease-modifying anti-rheumatic drugs (DMARDs). However, about 30% of patients experience failure of first-line anti-TNF agent because of inefficacy or adverse events. This study analyzed long-term anti-TNFα drug survival in a clinical practice setting. The overall 10-year retention rate of first-line anti-TNF agent is about 23%, being significantly higher for SpA compared with RA patients. ETN is the most persistent anti-TNF with a drug survival rate significantly higher than IFX and ADA.
Ten-Year Drug Survival of Anti-TNF Agents in the Treatment of Inflammatory Arthritides / M. Biggioggero, E.G. Favalli. - In: DRUG DEVELOPMENT RESEARCH. - ISSN 0272-4391. - 75:(2014 Nov), pp. S38-S41. [10.1002/ddr.21192]
Ten-Year Drug Survival of Anti-TNF Agents in the Treatment of Inflammatory Arthritides
M. BiggioggeroPrimo
Writing – Original Draft Preparation
;E.G. Favalli
Ultimo
Writing – Review & Editing
2014
Abstract
Postmarketing Phase IV Tumor necrosis factor (TNF) inhibitor therapies (anti-TNFs) are used routinely as first-line biotherapy for the treatment of rheumatoid arthritis (RA) and spondyloarthritis (SpA: psoriatic arthritis [PsA] and ankylosing spondylitis [AS]) in patients who have failed traditional non-biologic disease-modifying anti-rheumatic drugs (DMARDs). However, about 30% of patients experience failure of first-line anti-TNF agent because of inefficacy or adverse events. This study analyzed long-term anti-TNFα drug survival in a clinical practice setting. The overall 10-year retention rate of first-line anti-TNF agent is about 23%, being significantly higher for SpA compared with RA patients. ETN is the most persistent anti-TNF with a drug survival rate significantly higher than IFX and ADA.File | Dimensione | Formato | |
---|---|---|---|
Drug Development Research - 2014 - Biggioggero - Ten‐Year Drug Survival of Anti‐TNF Agents in the Treatment of Inflammatory.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
153.02 kB
Formato
Adobe PDF
|
153.02 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.